European Union - Croatian - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib фумарат - leukemija, mieloidna, akutna - antineoplastična sredstva - xospata prikazan kao monoterapija za liječenje odraslih pacijenata s relaps ili vatrostalne akutne mijeloične leukemije (aml) s перегласовкой flt3 na .

European Union - Croatian - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemijski pripravci - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

European Union - Croatian - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

European Union - Croatian - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilija a - antihemorrhagics - liječenje i profilaksu krvarenja u bolesnika s hemofilijom a (nedostatak prirođenih faktora viii). ovaj lijek ne sadrži faktor Виллебранда i stoga nije navedeno u bolest pozadina Виллебранда .

European Union - Croatian - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - narkolepsiju - ostali lijekovi protiv živčanog sustava - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.

European Union - Croatian - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

European Union - Croatian - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotska sredstva - xarelto, uvedene zajedno sa ацетилсалициловой kiselinom (ask) sami ili sa asc plus клопидогрел ili Тиклопидин, prikazana za prevenciju атеротромботических događaja kod odraslih pacijenata nakon akutnog koronarni sindrom (acs) s povišenom razinom кардиальных biomarkera. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

European Union - Croatian - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multipli mijelom - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

European Union - Croatian - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

European Union - Croatian - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibakterijski lijekovi za sistemsku primjenu, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika. pravilno korištenje antibakterijskih sredstava.